Ella Daly, MB, BCh, BAO

Esketamine Nasal Spray Combined With an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression: Results of a Double-Blind, Randomized Withdrawal, Multicenter Study (SUSTAIN-1)

Background: Numerous studies have demonstrated short-term efficacy of esketamine in treatment-resistant depression (TRD), whereas long-term antidepressant effects remain to be established...

John Zajecka , MD;

Madhukar Trivedi , MD;

Andrew Winokur , MD, PhD;

Wayne Drevets , MD;

Ilona Divacka , MBA, MD;

Jaskaran Singh , MD;

Andrea Fagiolini , MD;

Wieslaw Cubala , MD, PhD;

Xiang Li , PhD;

Pierre Blier , MD, PhD;

Rosanne Lane , MD, MSc, MS;

Richard Shelton , MD;

Pilar Lim , MD, PhD;

Patricio Molero , MD, PhD;

David Hough , MD;

Husseini Manji , MD;

Istvan Bitter , MD, PhD, DSc;

Adam Janik , MD;

Michael Thase , MD;

Honglan Li , MD, PhD;

Yun Zhang , PhD;

Anna Ducca , BSN;

Ella Daly , MB, BCh, BAO;

03/01/2019

US Mental Health Resource Utilization in Major Depressive Disorder With Suicidal Ideation

Introduction: Major depressive disorder (MDD) and suicidal ideation/behavior, both incur substantial mental health resource utilization (MHRU) burden, yet little is known of the burden of...

Ella Daly , MB, BCh, BAO;

Kun Wang , PhD;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Jennifer Voelker , MS, PharmD;

Jacqueline Pesa , PhD, MPH;

Nancy Connolly , MPH;

11/22/2019

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Assessment of Health-Related Quality of Life and Health Status in Patients With Treatment Resistant Depression Treated With Esketamine Nasal Spray Plus Oral Antidepressant Using European Quality of Life Group-5-Dimension-5-Level

Objective: To assess health-related quality of life (HRQoL) and health status of patients with treatment resistant depression (TRD), treated with esketamine nasal spray+oral antidepressan...

Vanina Popova , MD;

Ella Daly , MB, BCh, BAO;

Kimberly Cooper , MS;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

11/22/2019

Use of Patient Health Questionnaire to Predict Relapses Among Patients With Treatment-Resistant Depression Treated With Esketamine + Oral Antidepressant

Objective: To assess the Patient Health Questionnaire (PHQ-9) as a predictor of relapse of depressive symptoms in treatment-resistant depression (TRD).

Nan Li , PhD;

Adam Janik , MD;

Ella Daly , MB, BCh, BAO;

Rosanne Lane , MD, MSc, MS;

Jaskaran Singh , MD;

Carol Jamieson , BSc;

11/22/2019

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...

Ibrahim Turkoz , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

Stephane Borentain , MD;

Muideen Adigun , PharmD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;

Madhukar Trivedi , MD;

Michael Thase , MD;

Jaskaran Singh , MD;

Giacomo Salvadore , MD;

Maggie Fedgchin , PharmD;

H. Lynn Starr , MD, FAAP;

A. John Rush , MD;

11/22/2019

National Trends in the Prevalence of Major Depressive Disorder With Suicidal Ideation Among Adults Using National Survey on Drug Use and Health Data

Introduction: Although depression is a known risk factor for suicide, little is known about how the prevalence of co-occurring major depressive disorder (MDD) and suicidal ideation/behavi...

Ella Daly , MB, BCh, BAO;

Kun Wang , PhD;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Jennifer Voelker , MS, PharmD;

Jacqueline Pesa , PhD, MPH;

Nancy Connolly , MPH;

Ayush Srivastava , BS ;

11/22/2019

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

Craig Nelson , MD;

Carmine Rossi , PhD;

Ella Daly , MB, BCh, BAO;

Maryia Zhdanava , MA;

Harsh Kuvadia ;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

11/22/2019

How Well Do Real-World Clinical And Demographic Characteristics Predict Patient Health Questionnaire-9 Scores Among Patients With Treatment-Resistant Depression?

Background: Many real-world databases do not capture the Patient Health Questionnaire-9 (PHQ-9), a self-reported questionnaire used to measure depression severity. We created a model to p...

Xing Liu , MA;

Eros Papademetriou , MA;

Kruti Joshi , MPH, MD;

Ella Daly , MB, BCh, BAO;

Ravi Potluri ;

David Rotter ;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Anandaroop Dasgupta , PhD, MS;

11/22/2019